miR‐200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer

circKIF4A acts as a prognostic factor and mediator to regulate the progression of triple-negative breast cancer

(2019) Hailin Tang et al.   Molecular Cancer

WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells

(2016) LIANG XU et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer

(2016) L Castagnoli et al.   ONCOGENE

Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy

(2015) Daniel L. Abravanel et al.   JOURNAL OF CLINICAL INVESTIGATION

Notch1 Pathway Activation Results from the Epigenetic Abrogation of Notch-Related MicroRNAs in Mycosis Fungoides

(2015) Fernando Gallardo et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

(2015) Javier Cortés et al.   LANCET ONCOLOGY

miR-200c inhibits breast cancer proliferation by targeting KRAS

(2015) Cailu Song et al.   Oncotarget

GPR84 sustains aberrant  -catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis

(2014) P. A. Dietrich et al.   BLOOD

Genome-wide identification of miR-200 targets reveals a regulatory network controlling cell invasion

(2014) C. P. Bracken et al.   EMBO JOURNAL

miR-200c Inhibits invasion, migration and proliferation of bladder cancer cells through down-regulation of BMI-1 and E2F3

(2014) Lei Liu et al.   Journal of Translational Medicine

Wnt inhibitory factor 1 suppresses cancer stemness and induces cellular senescence

(2014) I Ramachandran et al.   Cell Death & Disease

Targeted delivery of miR-200c/DOC to inhibit cancer stem cells and cancer cells by the gelatinases-stimuli nanoparticles

(2013) Qin Liu et al.   BIOMATERIALS

Optical Metabolic Imaging Identifies Glycolytic Levels, Subtypes, and Early-Treatment Response in Breast Cancer

(2013) A. J. Walsh et al.   CANCER RESEARCH

Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2

(2013) B. N. Rexer et al.   CLINICAL CANCER RESEARCH

Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients

(2012) Lucia Del Mastro et al.   Expert Review of Anticancer Therapy

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

(2012) Ron Bose et al.   Cancer Discovery

Interaction of hsa-miR-381 and glioma suppressor LRRC4 is involved in glioma growth

(2011) Hailin Tang et al.   BRAIN RESEARCH

MicroRNA Regulation of Cancer Stem Cells

(2011) C. Liu et al.   CANCER RESEARCH

Sonic Hedgehog Pathway Promotes Metastasis and Lymphangiogenesis via Activation of Akt, EMT, and MMP-9 Pathway in Gastric Cancer

(2011) Y. A. Yoo et al.   CANCER RESEARCH

Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells

(2011) Diana M Vallejo et al.   EMBO JOURNAL

The JAK2/STAT3 signaling pathway is required for growth of CD44+CD24– stem cell–like breast cancer cells in human tumors

(2011) Lauren L.C. Marotta et al.   JOURNAL OF CLINICAL INVESTIGATION

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

(2011) Siyuan Zhang et al.   NATURE MEDICINE

Targeting Hedgehog -- a Cancer Stem Cell Pathway

(2010) A. A. Merchant et al.   CLINICAL CANCER RESEARCH

Targeting Notch to Target Cancer Stem Cells

(2010) A. Pannuti et al.   CLINICAL CANCER RESEARCH

The miR-200 family controls  -tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients

(2010) S. Leskela et al.   ENDOCRINE-RELATED CANCER

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

Loss of miR-200 Inhibition of Suz12 Leads to Polycomb-Mediated Repression Required for the Formation and Maintenance of Cancer Stem Cells

(2010) Dimitrios Iliopoulos et al.   MOLECULAR CELL

Targeting cancer stem cells by inhibiting Wnt, Notch and Hedgehog pathways

(2010) Naoko Takebe et al.   Nature Reviews Clinical Oncology

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib

(2009) R. M. Lemoli et al.   BLOOD

Immunoselection of Breast and Ovarian Cancer Cells with Trastuzumab and Natural Killer Cells: Selective Escape of CD44high/CD24low/HER2low Breast Cancer Stem Cells

(2009) F. Reim et al.   CANCER RESEARCH

Downregulation of miRNA-200c Links Breast Cancer Stem Cells with Normal Stem Cells

(2009) Yohei Shimono et al.   CELL

miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy

(2009) L. Adam et al.   CLINICAL CANCER RESEARCH

The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy

(2009) Yong Lin et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells

(2009) Sung Pil Hong et al.   INTERNATIONAL JOURNAL OF CANCER

Loss of miR-200c: A Marker of Aggressiveness and Chemoresistance in Female Reproductive Cancers

(2009) Dawn R. Cochrane et al.   Journal of Oncology

The miR-200 Family Inhibits Epithelial-Mesenchymal Transition and Cancer Cell Migration by Direct Targeting of E-cadherin Transcriptional RepressorsZEB1andZEB2

(2008) Manav Korpal et al.   JOURNAL OF BIOLOGICAL CHEMISTRY